Filtered By:
Procedure: Parenteral Nutrition
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 111 results found since Jan 2013.
Evidence summary on nutrition management for post-stroke dysphagia
CONCLUSIONS: This study summarized the evidence of the nutrition management for PSD patients. Since evidences are from different countries, it's better to assess the clinical environment and other related factors before their application.PMID:36505333 | PMC:PMC9730085
Source: American Journal of Translational Research - December 12, 2022 Category: Research Authors: Yuan Wang Lijun Xiang Yansi Luo Meng Cao Xuemei Song Jing Hong Xiaomei Zhang Source Type: research
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Association of nutritional support with survival-time in hospitalized older patients with dysphagia: a retrospective study
Dysphagia results from age-related changes in swallowing physiology and contributes to various health status changes, including higher risks for malnutrition, pneumonia, and mortality [1, 2]. It also occurs in age-related diseases, including stroke [3] and cancer [4], and progressive neurological diseases, such as dementia [5] and Parkinson ’s disease [6]. These associations, and global aging, have increased the importance of dysphagia management.
Artificial nutrition can support patients with dysphagia caused by various clinical conditions. Percutaneous endoscopic gastrostomy (PEG) is an artificial nutrition method that...
Source: Annals of Nutrition and Metabolism - July 13, 2022 Category: Nutrition Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
